Europe Virus-like Particles Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Hepatitis, Cancer/HPV, and Gaucher disease), Source (Yeast, Insect Cell, Plant, and Others), and Application (Vaccines and Therapeutics)

No. of Pages: 122    |    Report Code: TIPRE00026818    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
Europe Virus-like Particles Market

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. Europe Virus-like Particles Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. Europe Virus-like Particles Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1
  • 5.1.2 Rising demand for vaccine development.
  • 5.1.3 Increasing investments in biotech research.
  • 5.1.4 Growing prevalence of infectious diseases.
5.2 Market Opportunities
  • 5.2.1
  • 5.2.2 Expansion in cancer vaccine research.
  • 5.2.3 Development of VLP-based diagnostics.
  • 5.2.4 Increasing applications in gene therapy.
5.3 Future Trends
  • 5.3.1
  • 5.3.2 Rise in personalized VLP vaccines.
  • 5.3.3 Nanotechnology in VLP development.
  • 5.3.4 Focus on scalable VLP production.
5.4 Impact of Drivers and Restraints

6. Europe Virus-like Particles Market Regional Analysis

6.1 Europe Virus-like Particles Market Overview
6.2 Europe Virus-like Particles Market Revenue 2019-2028 (US$ Million)
6.3 Europe Virus-like Particles Market Forecast Analysis

7. Europe Virus-like Particles Market Analysis – by Product Type

7.1 Hepatitis
  • 7.1.1 Overview
  • 7.1.2 Hepatitis: Europe Virus-like Particles Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Cancer/HPV
  • 7.2.1 Overview
  • 7.2.2 Cancer/HPV: Europe Virus-like Particles Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Gaucher disease
  • 7.3.1 Overview
  • 7.3.2 Gaucher disease: Europe Virus-like Particles Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Virus-like Particles Market Analysis – by Source

8.1 Yeast
  • 8.1.1 Overview
  • 8.1.2 Yeast: Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Insect Cell
  • 8.2.1 Overview
  • 8.2.2 Insect Cell: Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
8.3 Plant
  • 8.3.1 Overview
  • 8.3.2 Plant: Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Virus-like Particles Market Analysis – by Application

9.1 Vaccines and Therapeutics
  • 9.1.1 Overview
  • 9.1.2 Plant: Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Virus-like Particles Market – Europe Analysis

10.1 Europe
  • 10.1.1 Europe Virus-like Particles Market Breakdown, by Key Country, 2022 and 2028 (%)
  • 10.1.1.1 Europe Virus-like Particles Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 UK: Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 UK: Europe Virus-like Particles Market Breakdown, by Product Type
    • 10.1.1.1.2 UK: Europe Virus-like Particles Market Breakdown, by Source
    • 10.1.1.1.3 UK: Europe Virus-like Particles Market Breakdown, by Application
  • 10.1.1.2 Germany: Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Germany: Europe Virus-like Particles Market Breakdown, by Product Type
    • 10.1.1.2.2 Germany: Europe Virus-like Particles Market Breakdown, by Source
    • 10.1.1.2.3 Germany: Europe Virus-like Particles Market Breakdown, by Application
  • 10.1.1.3 France: Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 France: Europe Virus-like Particles Market Breakdown, by Product Type
    • 10.1.1.3.2 France: Europe Virus-like Particles Market Breakdown, by Source
    • 10.1.1.3.3 France: Europe Virus-like Particles Market Breakdown, by Application
  • 10.1.1.4 Russia: Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.4.1 Russia: Europe Virus-like Particles Market Breakdown, by Product Type
    • 10.1.1.4.2 Russia: Europe Virus-like Particles Market Breakdown, by Source
    • 10.1.1.4.3 Russia: Europe Virus-like Particles Market Breakdown, by Application
  • 10.1.1.5 Italy: Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.5.1 Italy: Europe Virus-like Particles Market Breakdown, by Product Type
    • 10.1.1.5.2 Italy: Europe Virus-like Particles Market Breakdown, by Source
    • 10.1.1.5.3 Italy: Europe Virus-like Particles Market Breakdown, by Application
  • 10.1.1.6 Rest of Europe: Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.6.1 Rest of Europe: Europe Virus-like Particles Market Breakdown, by Product Type
    • 10.1.1.6.2 Rest of Europe: Europe Virus-like Particles Market Breakdown, by Source
    • 10.1.1.6.3 Rest of Europe: Europe Virus-like Particles Market Breakdown, by Application

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. Europe Virus-like Particles Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Merck & Co., Inc.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 GlaxoSmithKline plc.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Pfizer Inc.
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 Sanofi
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Serum Institute of India Pvt. Ltd.
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 BHARAT BIOTECH
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 LG Chem
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Dynavax Technologies
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - Europe Virus-like Particles Market

  1. Merck & Co., Inc.                                                       
  2. GlaxoSmithKline plc.                                                
  3. Pfizer Inc.                                                                    
  4. Sanofi                                                                         
  5. Serum Institute of India Pvt. Ltd.                           
  6. BHARAT BIOTECH                                                      
  7. LG Chem                                                                     
  8. Dynavax Technologies